Journal article
The impact of hospital costing methods on cost-effectiveness analysis: a case study
- Abstract:
- Background Several methods exist to cost hospital contacts when estimating the cost effectiveness of a new intervention. However, the implications of choosing a particular approach remain unclear. We compare the use of the three main diagnosis-related group (DRG)-based national unit costs in England to determine whether choice of approach can impact on economic evaluation results. Methods A cost-utility model was developed to compare secondary fracture prevention models of care for hip fracture patients, using data from large primary and hospital care administrative datasets in England. A healthcare and personal social services payer perspective was adopted, and utilities were informed by a meta-regression. Hospital resource use was valued using three DRG-based unit costs, and regression-based costing models were developed using data from 13,906 patients to inform the model health states. Results Finished consultant episode (FCE)-level reference costs resulted in the highest costs on admission (£9075) and in the year of the fracture (£14,440). Relative to FCE-level costs, spell-level tariffs led to the lowest total hospital care costs per patient within 1 year of fracture (− £3691) compared with spell-level reference costs (− £2106). At a £20,000/quality-adjusted life-year threshold, using spell-level reference costs or spell-level tariffs, the introduction of a nurse-led fracture liaison service model of care was the cost-effective alternative. However, using FCE-level reference costs, usual care was the cost-effective option. Conclusions Our results show that, conditional on the set of national unit costs adopted, the costs of hip fracture may vary considerably and different decisions may be reached regarding the introduction of new healthcare interventions.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 773.3KB, Terms of use)
-
- Publisher copy:
- 10.1007/s40273-018-0673-y
Authors
- Publisher:
- Springer
- Journal:
- PharmacoEconomics More from this journal
- Volume:
- 36
- Issue:
- 10
- Pages:
- 1263–1272
- Publication date:
- 2018-05-22
- Acceptance date:
- 2018-05-07
- DOI:
- EISSN:
-
1179-2027
- ISSN:
-
1170-7690
- Keywords:
- Pubs id:
-
pubs:846603
- UUID:
-
uuid:88c56fb6-378b-41fa-90b3-6c5be3c146b1
- Local pid:
-
pubs:846603
- Source identifiers:
-
846603
- Deposit date:
-
2018-05-08
- ARK identifier:
Terms of use
- Copyright holder:
- Leal et al
- Copyright date:
- 2018
- Notes:
-
Copyright © The Authors 2018. This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
If you are the owner of this record, you can report an update to it here: Report update to this record